-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Chemed, Lowers Price Target to $500

Benzinga·02/27/2026 15:15:44
Listen to the news
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $580 to $500.